Lebrikizumab (Ebglyss)

Indications

Treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years of age and older with a body weight of at least 40kg who are candidates for systemic therapy.

Contraindications

Hypersensitivity to the active substance or to any of the excipients

Sizes Available

A subcutaneous injection of the monoclonal antibody lebrikizumab for the treatment of moderate-to-severe psoriasis.

More on: Systemic eczema treatments